2009.12.03 Weekly Broadcast Email
The following adverse events were reported during the month of November.
*** At the annual meeting, many site members suggested posting AEs on our website. We appreciate your suggestions and therefore, individual Adverse Events for open protocols are now available on the Research Base website under Patient Registration. To access these AEs, enter your CCRBIS username and password, click “Information” in the top left-hand corner, and choose the AE using the buttons and drop-down menu in the middle of the page. A PDF of the AE document has also been attached to this email and a summary of the event can be found on the adverse event page of the website. Please contact Sarah Hahne at firstname.lastname@example.org if you have any questions.
In the month of November, 9 patients were accrued to CCCWFU CCOP Research Base trials. CTSU was the top accruing site with 4 patients. See the Research Base website spotlight section for further information.
Featured Study: Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients
Have you considered opening 91105 at your site? Has your site accrued patients to this study recently? You might be interested to know…
Several recent protocol changes have been made to study 91105, Phase III Double Blind, Placebo Controlled Study of Donepezil in Irradiated Brain Tumor Patients. These changes were made to facilitate and simplify enrollment which include:
-Adding a $40 gift for participating
-Simplifying and reducing medication exclusions
Visit the recently updated 91105 webpage to view:
- Letter from the PI, Dr. Steve Rapp
- Brochure outlining recent changes
- Training video
97106 (Randomized Study to Determine whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors)only has 8 minority accrual slots open for patient accruals. We would like to see this study close by the end of the year, so if you have patients that may be eligible for this study, please try and get them registered by then.